SS
SAGE

SBI Securities’s Sage Therapeutics SAGE Stock Holding History

SBI Securities’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3
Closed -$27 – 4294
2025
Q2 		$27 Sell
3
-2
-40% -$15 ﹤0.01% 3862
2025
Q1 		$40 Sell
5
-5
-50% -$37 ﹤0.01% 3703
2024
Q4 		$54 Buy
+10
New +$61 ﹤0.01% 3622

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SBI Securities's SAGE Position: Q3 2025 in Review

SBI Securities sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 3 shares — an estimated $27 sold.

SBI Securities first reported a position in SAGE in Q4 2024 and held it in 3 quarters. The position peaked at $54 in Q4 2024. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • SBI Securities reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • SBI Securities sold 3 Sage Therapeutics shares in Q3 2025, an estimated $27.
  • SBI Securities first reported a position in Sage Therapeutics in Q4 2024 and held it in 3 quarters.
  • SBI Securities's Sage Therapeutics position peaked at $54 in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.